China Health Technology Group Holding Company Limited (HK:1069) announced the appointment of Mr. Li Zhiliang as the Chief Executive Officer of its subsidiary, Genmao (Shenzhen) Biotechnology Co., Ltd.
Mr. Li brings with him over two decades of experience in the acer truncatum industry. He has been involved in national projects and standard-setting initiatives related to this sector. The company anticipates that his leadership will strengthen its technological capabilities and enhance its brand’s influence, ultimately benefiting long-term shareholder value.
China Health Technology Group operates within the biotechnology sector, specializing in the development of the acer truncatum industrial chain. Its primary focus is on the functional food and oil markets.
As of current market data:
- YTD Price Performance: -2.50%
- Average Trading Volume: 1,760,747
- Technical Sentiment Consensus Rating: Buy
- Current Market Cap: HK$34.37M
Detailed analytics on 1069 stock are available on TipRanks’ Stock Analysis page.
